{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,9]],"date-time":"2026-03-09T16:59:06Z","timestamp":1773075546776,"version":"3.50.1"},"reference-count":17,"publisher":"Elsevier BV","issue":"10","license":[{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,10,1]],"date-time":"2020-10-01T00:00:00Z","timestamp":1601510400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K12CA167540"],"award-info":[{"award-number":["K12CA167540"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000133","name":"Agency for Healthcare Research and Quality","doi-asserted-by":"publisher","award":["R24 HS19455"],"award-info":[{"award-number":["R24 HS19455"]}],"id":[{"id":"10.13039\/100000133","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","clinical-lymphoma-myeloma-leukemia.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Lymphoma Myeloma and Leukemia"],"published-print":{"date-parts":[[2020,10]]},"DOI":"10.1016\/j.clml.2020.04.018","type":"journal-article","created":{"date-parts":[[2020,5,7]],"date-time":"2020-05-07T04:52:40Z","timestamp":1588827160000},"page":"647-651","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":21,"title":["Racial Disparities in the Utilization of Novel Agents for Frontline Treatment of Multiple Myeloma"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0208-5023","authenticated-orcid":false,"given":"Mark A.","family":"Fiala","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1479-7626","authenticated-orcid":false,"given":"Tanya M.","family":"Wildes","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi","family":"Vij","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.clml.2020.04.018_bib1","doi-asserted-by":"crossref","first-page":"1590","DOI":"10.1002\/cncr.30526","article-title":"Racial disparities in treatment utilization for multiple myeloma","volume":"123","author":"Fiala","year":"2017","journal-title":"Cancer"},{"key":"10.1016\/j.clml.2020.04.018_bib2","doi-asserted-by":"crossref","first-page":"2876","DOI":"10.1002\/cam4.1246","article-title":"Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a SEER-Medicare analysis","volume":"6","author":"Ailawadhi","year":"2017","journal-title":"Cancer Med"},{"key":"10.1016\/j.clml.2020.04.018_bib3","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1524-4733.2009.00679.x","article-title":"Factors influencing cost-related nonadherence to medication in older adults: a conceptually based approach","volume":"13","author":"Zivin","year":"2010","journal-title":"Value Health"},{"key":"10.1016\/j.clml.2020.04.018_bib4","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1007\/s11764-015-0499-y","article-title":"Racial and ethnic disparities in cost-related medication non-adherence among cancer survivors","volume":"10","author":"Lee","year":"2016","journal-title":"J\u00a0Cancer Surviv"},{"key":"10.1016\/j.clml.2020.04.018_bib5","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1007\/s40271-017-0235-y","article-title":"Patients\u2019 preferences for outcome, process and cost attributes in cancer treatment: a systematic review of discrete choice experiments","volume":"10","author":"Bien","year":"2017","journal-title":"Patient"},{"key":"10.1016\/j.clml.2020.04.018_bib6","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.3109\/10428194.2015.1011156","article-title":"Socioeconomic status is independently associated with overall survival in patients with multiple myeloma","volume":"56","author":"Fiala","year":"2015","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.clml.2020.04.018_bib7","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1634\/theoncologist.2012-0113","article-title":"Health care costs and resource utilization, including patient burden, associated with novel-agent\u2013based treatment versus other therapies for multiple myeloma: findings using real-world claims data","volume":"18","author":"Teitelbaum","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.clml.2020.04.018_bib8","doi-asserted-by":"crossref","first-page":"IV3","DOI":"10.1097\/00005650-200208001-00002","article-title":"Overview of the SEER-Medicare data: content, research applications, and generalizability to the United States elderly population","volume":"40","author":"Warren","year":"2002","journal-title":"Med Care"},{"key":"10.1016\/j.clml.2020.04.018_bib9","article-title":"Development of an algorithm to distinguish smoldering versus symptomatic multiple myeloma in claims-based data sets","volume":"1","author":"Fiala","year":"2017","journal-title":"JCO Clin Cancer Inform"},{"key":"10.1016\/j.clml.2020.04.018_bib10","doi-asserted-by":"crossref","first-page":"1258","DOI":"10.1016\/S0895-4356(00)00256-0","article-title":"Development of a comorbidity index using physician claims data","volume":"53","author":"Klabunde","year":"2000","journal-title":"J\u00a0Clin Epidemiol"},{"key":"10.1016\/j.clml.2020.04.018_bib11","doi-asserted-by":"crossref","first-page":"4808","DOI":"10.1182\/blood-2011-04-348367","article-title":"Addition of rituximab to chemotherapy alone as first-line therapy improves overall survival in elderly patients with mantle cell lymphoma","volume":"118","author":"Griffiths","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.04.018_bib12","author":"Cubanski"},{"key":"10.1016\/j.clml.2020.04.018_bib13","first-page":"3108","article-title":"A\u00a0cost\u2013benefit analysis of bortezomib, lenalidomide, and bortezomib\/lenalidomide combination therapy for newly diagnosed multiple myeloma","volume":"130","author":"Fiala","year":"2017","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.04.018_bib14","series-title":"Unequal Treatment: Confronting Racial and Ethnic Disparities in Health Care","author":"Smedley","year":"2003"},{"key":"10.1016\/j.clml.2020.04.018_bib15","doi-asserted-by":"crossref","first-page":"3586","DOI":"10.1182\/blood-2018-99-112921","article-title":"Patient preferences for multiple myeloma (MM) treatment: interim analysis of a discrete choice experiment","volume":"132","author":"McKay","year":"2018","journal-title":"Blood"},{"key":"10.1016\/j.clml.2020.04.018_bib16","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1182\/blood-2018-99-113087","article-title":"Patient treatment preferences for relapsed\/refractory multiple myeloma: are patients willing to trade off efficacy for tolerability?","volume":"132","author":"Auclair","year":"2018","journal-title":"Blood"},{"issue":"suppl 1","key":"10.1016\/j.clml.2020.04.018_bib17","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1177\/1077558700057001S10","article-title":"Race, ethnicity, and the health care system: public perceptions and experiences","volume":"57","author":"Lillie-Blanton","year":"2000","journal-title":"Med Care Res Rev"}],"container-title":["Clinical Lymphoma Myeloma and Leukemia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020302135?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2152265020302135?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T00:36:19Z","timestamp":1761870979000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2152265020302135"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10]]},"references-count":17,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2020,10]]}},"alternative-id":["S2152265020302135"],"URL":"https:\/\/doi.org\/10.1016\/j.clml.2020.04.018","relation":{},"ISSN":["2152-2650"],"issn-type":[{"value":"2152-2650","type":"print"}],"subject":[],"published":{"date-parts":[[2020,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Racial Disparities in the Utilization of Novel Agents for Frontline Treatment of Multiple Myeloma","name":"articletitle","label":"Article Title"},{"value":"Clinical Lymphoma Myeloma and Leukemia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clml.2020.04.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}